HYPERBARIC OXYGEN THERAPY CLINIC BUSINESS PLAN

I. Executive Summary

Company Description

Oasis Hyperbaric Clinic (name chosen to reflect restoration and elevated healing) is an advanced medical clinic in Austin, Texas, launching in 2026 that specializes in physician‑supervised hyperbaric oxygen therapy (HBOT). We operate in the healthcare and wellness sectors and deliver treatments using FDA‑cleared monoplace acrylic chambers. Our core services are clinical HBOT for wound care and post‑procedure recovery plus premium wellness protocols. The clinical team includes a Medical Director, Certified Technologists, and Registered Nurses focused on patient safety and outcomes. One line: Restorative, physician‑led HBOT delivered in a boutique, high‑comfort setting.

We run scheduled treatment sessions, physician evaluations, and outcome tracking to bridge hospital wound care and upscale wellness. Competitive advantages are the use of FDA‑cleared monoplace chambers, physician oversight, and a high‑comfort patient experience that reduces anxiety and improves adherence. Target customers are adults in the Austin metro area with chronic or non‑healing wounds, post‑surgical recovery needs, and wellness clients seeking recovery optimization. Short‑term goal: open in 2026 and achieve 300 treatments/month by month 12. Long‑term goal: scale to two additional Texas locations within five years while maintaining clinical outcomes and >85% patient satisfaction.

Problem

Chronic non-healing wounds—especially diabetic foot ulcers and radiation injuries—produce prolonged pain, infection risk, repeat hospital visits, and higher lifetime medical costs across the U.S. healthcare system.

There is a shortage in the Austin, Texas metropolitan area of clinics that combine hospital-grade, physician-supervised hyperbaric oxygen therapy (HBOT) with a boutique, high-comfort patient experience using FDA-cleared monoplace acrylic chambers.

As a result, patients face increased infections and readmissions, longer recovery and functional loss, limited access to advanced oxygen therapies, and fewer options for athletic and wellness recovery—creating a clear need for a specialized HBOT clinic launching in 2026.

Solution

Patients with chronic wounds and radiation injuries face slow, fragmented recovery and limited access to clinical-grade treatments. Our clinic provides physician-supervised hyperbaric oxygen therapy (HBOT) in private monoplace acrylic chambers, following FDA-approved medical protocols plus off-label wellness and athletic protocols to accelerate healing, reduce inflammation, and improve recovery outcomes while delivering a premium outpatient experience.

One-liner: Physician-supervised HBOT in private chambers that accelerates healing and supports wellness goals.

Mission Statement

Our mission is to accelerate recovery and enhance vitality through personalized, physician-monitored hyperbaric oxygen therapy delivered in a safe, comfortable, boutique setting. We commit to evidence-based clinical outcomes, clinical excellence, and measurable improvements in patients’ quality of life. We aim to be the premier partner for referring physicians and the first choice for wellness-oriented individuals while advancing regenerative medicine with patient-focused innovation.

Key Success Factors

Critical capabilities that will drive clinic performance and patient trust.

• Licensed Medical Director provides highest-level clinical oversight and safety.
• Strategic partnerships with local surgeons and hospitals secure a consistent referral pipeline.
• Boutique environment with private acrylic chambers differentiates from institutional competitors.
• Operational efficiency supporting a projected 16-month payback period.
• Growing longevity and anti-aging demand creates a high-margin secondary revenue stream.

Financial Summary

Executive Summary financial snapshot: Year 1 EBITDA of $1,128,000 and a fast 16-month payback. One-liner: Year 1 EBITDA $1,128,000; payback 16 months.

Financial requirements: total initial capex $1,200,000 and minimum cash requirement $166,000 (minimum cash month: Jun-26). One-liner: Capex $1,200,000; minimum cash $166,000; breakeven Jan-26; 16-month payback.

Outlook: the model delivers strong cash generation and scales to $7,188,000 EBITDA by 2030.

Funding Requirements

We need USD 1,816,000 to launch; projected Year 1 EBITDA is USD 1,128,000, IRR 11%, ROE 21.36%, EBITDA reaches USD 7,188,000 by 2030, and payback is 16 months.